In the same way, while the type of irAEs after the first ICI treatment is generally well-described (e.g., colitis, hypophysitis and rash are more frequently described with anti-CTLA-4 and pneumonitis, hypothyroidism, arthralgia and vitiligo with anti-PD-1) [13], data remain unclear and heterogeneous on the type of second irAEs according to the type of ICI resuming. This evidence concerns the gene PDCD1 and hypophysitis.